Overexpression of Insulin Receptor Substrate 1 (IRS1) Relates to Poor Prognosis and Promotes Proliferation, Stemness, Migration, and Oxidative Stress Resistance in Cholangiocarcinoma.
Humans
Insulin Receptor Substrate Proteins
/ genetics
8-Hydroxy-2'-Deoxyguanosine
/ metabolism
Bile Duct Neoplasms
/ metabolism
Cholangiocarcinoma
/ metabolism
Inflammation
/ metabolism
Oxidative Stress
Bile Ducts, Intrahepatic
/ metabolism
Cell Proliferation
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
cholangiocarcinoma
insulin receptor substrate 1
oxidative stress
tumor progression
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Jan 2023
26 Jan 2023
Historique:
received:
09
12
2022
revised:
13
01
2023
accepted:
24
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
Cholangiocarcinoma (CCA) is one of the oxidative stress-driven carcinogenesis through chronic inflammation. Insulin receptor substrate 1 (IRS1), an adaptor protein of insulin signaling pathways, is associated with the progression of many inflammation-related cancers. This study hypothesized that oxidative stress regulates IRS1 expression and that up-regulation of IRS1 induces CCA progression. The localizations of IRS1 and an oxidative stress marker (8-oxodG) were detected in CCA tissues using immunohistochemistry (IHC). The presence of IRS1 in CCA tissues was confirmed using immortal cholangiocyte cells (MMNK1), a long-term oxidative-stress-induced cell line (ox-MMNK1-L), and five CCA cell lines as cell culture models. IRS1 was overexpressed in tumor cells and this was associated with a shorter patient survival time and an increase in 8-oxodG. IRS1 expression was higher in ox-MMNK1-L cells than in MMNK1 cells. Knockdown of IRS1 by siRNA in two CCA cell lines led to inhibition of proliferation, cell cycle progression, migration, invasion, stemness, and oxidative stress resistance properties. Moreover, a transcriptomics study demonstrated that suppressing IRS1 in the KKU-213B CCA cell line reduced the expression levels of several genes and pathways involved in the cellular functions. The findings indicate that IRS1 is a key molecule in the connection between oxidative stress and CCA progression. Therefore, IRS1 and its related genes can be used as prognostic markers and therapeutic targets for CCA therapy.
Identifiants
pubmed: 36768755
pii: ijms24032428
doi: 10.3390/ijms24032428
pmc: PMC9916965
pii:
doi:
Substances chimiques
Insulin Receptor Substrate Proteins
0
8-Hydroxy-2'-Deoxyguanosine
88847-89-6
IRS1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Sci Rep. 2015 Jun 19;5:11471
pubmed: 26088427
Cell Commun Signal. 2009 Jun 17;7:14
pubmed: 19534786
Oncol Res. 2019 Mar 29;27(4):459-467
pubmed: 29495974
BMC Cancer. 2020 Oct 27;20(1):1028
pubmed: 33109107
Breast Cancer Res Treat. 2010 Oct;123(3):651-60
pubmed: 19924529
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):518-24
pubmed: 18349269
World J Gastroenterol. 2004 Feb 1;10(3):415-8
pubmed: 14760769
Hum Pathol. 2018 Sep;79:9-17
pubmed: 29551677
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W169-75
pubmed: 17576678
Carcinogenesis. 2011 Mar;32(3):389-98
pubmed: 21112960
Biochem Biophys Res Commun. 2015 Aug 14;464(1):182-8
pubmed: 26100205
Transplantation. 2004 Feb 15;77(3):446-51
pubmed: 14966424
Genes Dev. 2009 Dec 1;23(23):2729-41
pubmed: 19952108
Biomolecules. 2019 Jul 07;9(7):
pubmed: 31284679
Parasitol Int. 2012 Mar;61(1):130-5
pubmed: 21704729
Development. 2014 Apr;141(8):1614-26
pubmed: 24715453
Hum Cell. 2020 Jul;33(3):695-708
pubmed: 32207095
Int J Clin Exp Pathol. 2018 Nov 01;11(11):5185-5193
pubmed: 31949598
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
J Vis Exp. 2011 May 06;(51):
pubmed: 21587162
Oncogene. 2008 Jan 10;27(3):397-403
pubmed: 17700539
Anticancer Res. 2018 Apr;38(4):1937-1946
pubmed: 29599309
Oncogene. 2007 May 14;26(22):3159-71
pubmed: 17496913
Mol Cell Biol. 2006 Dec;26(24):9302-14
pubmed: 17030631
Int J Mol Med. 2021 Apr;47(4):
pubmed: 33604683
Int J Mol Med. 2019 Mar;43(3):1203-1216
pubmed: 30628663
J Endocrinol. 2008 May;197(2):287-96
pubmed: 18434358
J Cancer. 2021 Mar 5;12(9):2673-2686
pubmed: 33854627
Biochimie. 2005 Jan;87(1):99-109
pubmed: 15733744
Mutat Res. 2010 Sep 10;691(1-2):9-16
pubmed: 20541562
PLoS One. 2012;7(4):e36190
pubmed: 22558377
Carcinogenesis. 2004 Aug;25(8):1535-42
pubmed: 15059927
Nat Cell Biol. 2006 Oct;8(10):1114-23
pubmed: 16980957
Redox Biol. 2018 Apr;14:637-644
pubmed: 29169115
Diabetologia. 2006 Oct;49(10):2463-73
pubmed: 16896943
Int J Mol Sci. 2014 Dec 24;16(1):193-217
pubmed: 25547488
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):310-8
pubmed: 20056652
Mediators Inflamm. 2012;2012:165879
pubmed: 22577245
Nat Rev Gastroenterol Hepatol. 2011 Aug 02;8(9):512-22
pubmed: 21808282
Onco Targets Ther. 2016 Aug 24;9:5297-305
pubmed: 27601921
Cancer Lett. 2014 Nov 28;354(2):320-8
pubmed: 25194504
J Cell Physiol. 2012 Aug;227(8):2992-3000
pubmed: 22454254
Oncotarget. 2015 Jul 10;6(19):17206-20
pubmed: 26015398
J Biomed Sci. 2012 Jul 12;19:64
pubmed: 22788551
Oncol Lett. 2021 Sep;22(3):642
pubmed: 34386064
Cell Mol Biol (Noisy-le-grand). 2017 Jan 30;63(1):1-5
pubmed: 28234626
Free Radic Biol Med. 2009 Nov 15;47(10):1486-93
pubmed: 19703555